eliver holistic, individualized and science-led solutions that address growing patient needs, such as aesthetic changes related to menopause and medication-driven weight loss



ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable Restylane range, in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for the face and body.1-7Data includes an analysis from a first-of-its-kind study evaluating optimal treatment sequencing to enhance women’s skin during menopause, and an evaluation of the cellular makeup of fat in the abdomen following medication-driven weight loss.1,2

The two IITs were designed and executed by Dr. Andreas Nikolis and Dr. Sabrina Fabi respectively.1,2Galderma pr
=*=*=*=*=*=
当前为第2/13页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页